Teva receives CRL for reformulated schizophrenia drug developed with French biotech
Though Teva Pharmaceuticals is largely known for its biosimilars business, it still engages in the occasional, traditional research agreements with smaller biotechs. But one such …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
